XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.21.2

Subsequent Events | 9 Months Ended
--- | ---
Sep. 30, 2021
Subsequent Events |
Subsequent Events | 14. Subsequent Events Affitech Agreement On October 6, 2021, the Company entered into a commercial payment purchase agreement (the “Affitech Agreement”) with Affitech Research AS (“Affitech”), a Norwegian biotech company. Pursuant to the Affitech Agreement, the Company purchased a future stream of commercial payment rights to F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc.’s faricimab from Affitech for $6.0 million. The Company is eligible to receive 0.50% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. The Company may pay up to an additional $20.0 million to Affitech based upon the achievement of certain regulatory and sales milestones. Novartis International NIS793 Milestone On November 3, 2021, the Company was notified it had earned a $35.0 million milestone payment pursuant to the Anti-TGFβ Antibody License Agreement. The milestone was triggered upon dosing of the first patient in Novartis’ NIS793 Phase 3 clinical trial in October 2021. ​

X
- References No definition available. + Details
Name: | us-gaap_SubsequentEventsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -URI http://asc.fasb.org/topic&trid=2122774 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 855 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662 + Details
Name: | us-gaap_SubsequentEventsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration